Sep 19, 2023

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab) read more...

Aug 31, 2023

BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference read more...

Aug 02, 2023

BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results read more...

Jul 21, 2023

BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC read more...

Jul 12, 2023

BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication read more...

Jul 10, 2023

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors read more...

Jul 07, 2023

BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023 read more...

Jun 15, 2023

BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics read more...

Jun 15, 2023

BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma read more...

Jun 09, 2023

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress read more...

May 30, 2023

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia read more...

May 25, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio read more...

May 24, 2023

BeiGene to Present at Upcoming Investor Conferences read more...

May 17, 2023

The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries read more...

May 06, 2023

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China read more...

May 04, 2023

BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments read more...

Apr 26, 2023

BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting read more...

Apr 25, 2023

BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report read more...

Apr 20, 2023

BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma read more...

Apr 17, 2023

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 read more...

News Details